成功案例｜生物医药创业高管的 EB-1A 获批之路 | Case Study: EB-1A Approval for a Biotech Founder & Executive

一句话总结 (TL;DR)：一位拥有美国名校 MBA、在中美两地推动生物医药创业的女性高管，由新未名律所合伙人杨谦律师（qian.yang@nwmlaw.com）操刀，成功取得 EB-1A 杰出人才移民批准。本案获批的真正关键，不是材料的堆砌，而是主线的提炼——把"专业著作 + 媒体报道 + 公司创办 + 融资落地 + 美国布局 + 行业评审 + 奖项"重新拧成一条主线：能在生物医药行业形成稳定影响力，并把行业判断转化为公司和项目成果的创业者。本案对所有生物医药、医疗健康、创新创业方向的大华府DMV地区申请人都有直接借鉴意义。靠谱华人移民律师的价值，就在于把"做过什么"翻译成"在行业里是什么位置"。
TL;DR (English): A biotech founder and executive with a top U.S. MBA, operating in both China and the U.S., obtained EB-1A approval through New Weiming Law Group (partner attorney Qian Yang, qian.yang@nwmlaw.com). The decisive factor was not the volume of evidence but the construction of a single coherent narrative: a founder who has built sustained industry influence and converted that influence into real companies, financing, and U.S. operations. The case is directly instructive for biotech, healthcare, and innovation-driven applicants across the Greater Washington DMV Area, Maryland, and Virginia.

Q1. 申请人的职业背景是什么？ | What is the applicant's professional background?

中文：申请人是一名活跃于中美两地的生物医药创业者，拥有美国名校 MBA 背景，长期从事生物医药企业战略、公司管理和创新项目推进。在职业发展中，她逐步形成了"行业判断力 + 资源整合能力 + 企业落地能力"的复合型优势——既能洞察行业趋势，又能搭建团队、推动融资、把业务真正跑起来。她在中国创办公司之后，进一步在美国设立业务平台，把事业版图延伸到美国首都华盛顿地区所辐射的全美生物医药生态。

English: The applicant is a biotech entrepreneur operating in both China and the U.S., holding an MBA from a top American business school. Her career combines industry insight, resource integration, and operational execution — building strategy, leading teams, securing financing, and turning ideas into running businesses. After founding her company in China, she expanded into the U.S. with a dedicated operating entity.

Q2. EB-1A 的法律标准是什么？为什么创业高管也能走？ | What is the EB-1A legal standard, and why can founders/executives qualify?

中文：EB-1A 杰出人才移民依据 INA §203(b)(1)(A) 与 8 CFR §204.5(h)，要求申请人在科学、艺术、教育、商业或体育领域具有 Sustained National or International Acclaim，并满足"十项标准"中的至少三项，再通过 Final Merits Determination 整体评估。对生物医药创业高管而言，常见可命中的标准包括：

• Original Contributions of Major Significance（重大原创贡献——公司、产品、模式、行业方法论）；
• Authorship of Scholarly / Professional Articles（专业著作与行业文章）；
• Published Material About the Applicant（专业媒体与大众媒体报道）；
• Judging the Work of Others（行业评审、创业大赛评委、专业组织评审）；
• Leading or Critical Role for Distinguished Organizations（在具有突出声誉的公司/机构担任核心角色）；
• Awards and Recognition（行业奖项与荣誉）；
• High Remuneration（与同行相比明显较高的报酬）。

English: EB-1A requires sustained national or international acclaim and satisfaction of at least three of the ten regulatory criteria, followed by a final merits determination. Biotech founders and executives often hit criteria for original contributions, authorship, published material, judging, leading or critical role, awards, and high remuneration — provided each criterion is documented as more than résumé fodder.

Q3. 本案的第一个关键：为什么"行业影响力"比"工作年限"更重要？ | Why does industry influence outweigh years of experience?

中文：这位申请人最大的优势，并非"在行业里工作很多年"，而是她已经在行业里建立了可见度。她有专业著作，有持续的行业发声，并且被多家专业媒体和大众媒体采访报道。当这些材料汇聚在一起，传递的信号就不再是"一位资深从业者"，而是"一位被行业持续关注与讨论的人"。

EB-1A 看重的，从来不是工作年限的累计，而是申请人是否已经在所在领域建立了超出一般从业者的认可度。本案的说服力，恰恰在于她的影响并非靠"我很专业"这样的自述来证明，而是通过公开报道、行业传播和外部关注来呈现——这正是 Final Merits Determination 中最被移民官认可的"硬证据"。

English: Her strength is not tenure but visibility. Authored articles, sustained public commentary, and coverage by both trade and mainstream media transform her from a "senior practitioner" into a "consistently discussed industry figure." EB-1A weighs recognition far more than years of service, and external corroboration is exactly what officers credit in the final merits determination.

Q4. 第二个关键：创业类申请为什么必须"落到实物成果"？ | Why must founder-track cases be grounded in tangible results?

中文：创业类 EB-1A 最常见的失败模式，是只讲愿景、不见成果。本案不一样：申请人不仅创办了公司，还在较短时间内完成融资、搭建团队、建立项目布局，并把业务延伸到美国。这些事实把"能力"从纸面计划转化成了现实执行——这恰恰是 USCIS 在评估创业者时最看重的部分。

• 公司成立 → 证明把判断落成实体的能力；
• 融资进展 → 证明获得资本市场和投资方认可；
• 团队搭建 → 证明组织能力和领导力（呼应 Leading / Critical Role）；
• 项目布局 → 证明可持续推进的业务结构；
• 美国布局 → 证明 Future Plans to Continue Work in the U.S. 的具象路径。

English: Founder petitions fail when they stop at vision. This case demonstrated execution: a company formed, financing secured, a team assembled, projects rolled out, and a U.S. footprint established. Officers reviewing EB-1A founders specifically look for whether ability has been converted into outcomes, and these facts speak directly to that test.

Q5. 第三个关键：为什么"多层外部认可"比单一奖项更有分量？ | Why does layered external recognition outweigh a single award?

中文：除了媒体报道，申请人还拥有行业奖项、专业组织邀请、活动发言、评审经历，以及业内人士的肯定。这些材料分别来自不同层面，但都在指向同一件事：她在这个行业里不是普通从业者，而是被行业持续认可的人。

• 奖项 → 说明她"被看见"；
• 评审经历 → 说明她"有资格评价别人"（直接命中 Judging Criterion）；
• 专业协会与行业活动 → 说明她"被行业接纳"；
• 媒体和著作 → 说明她的"观点具有传播价值"。

English: Awards show she is seen; judging shows she is qualified to evaluate others; association invitations and speaking roles show industry acceptance; media coverage and authored work show her ideas travel. Each layer reinforces the others, mapping cleanly onto multiple EB-1A criteria simultaneously.

Q6. 第四个关键：她在美国的价值如何被"具象化"？ | How is her U.S. value made concrete?

中文：EB-1A 要求申请人"将持续从事其专长领域、并将实质性地有益于美国（substantially prospectively benefit the United States）"。本案中，申请人已经在美国设立公司、投入资金、推动业务实质开展。美国公司的实体存在、明确的资金投入和已签署的业务安排，使"未来贡献"从抽象的承诺变成可被审核的事实——这是创业类 EB-1A 写"Future Plans"段落时最稀缺的弹药。

English: EB-1A demands a credible plan to continue work in the U.S. for substantial prospective benefit. Here, a U.S. entity, capital deployed, and concrete operating arrangements turned an otherwise abstract "future plans" section into verifiable fact — the rarest and most persuasive form of evidence in founder petitions.

Q7. 第五个关键：复合型人才的优势怎么呈现？ | How is a hybrid-skill founder's advantage presented?

中文：申请人既能做行业判断，又能推动公司真正运转，还能把资源、团队和项目连接起来。这种复合型能力在创业类申请中分量极大，因为它直接对应 EB-1A 评估中"Leading or Critical Role + Original Contribution + Continued Endeavor"三项的交叉点。我们在材料组织时，刻意避免把她切割成"作者""管理者""创业者"三个互不相干的身份，而是统一成一个能解决行业真问题的复合型领袖。

Q8. 新未名律所是如何梳理这个案件的？ | How did New Weiming Law Group structure this case?

中文：创业类申请最常见的问题不是材料少，而是材料杂——著作、媒体、公司、融资、奖项、评审一项项罗列出来，看似丰富，实则各说各话，主线模糊。在本次申请中，新未名律所采取了"主线先行"的方法论：

• 先把申请人的核心身份精确定义为："在生物医药行业形成稳定影响力，并能把行业认知转化为公司和项目成果的创业者"；
• 围绕这一主线重新组织所有证据，让每一份材料都为同一论点服务，避免"什么都做过却不够集中"；
• 在 Petition Letter 中，按 EB-1A 法定标准逐条对应，并在 Final Merits 部分构建闭环逻辑；
• 在 Recommendation Letters 中，区分 Independent Experts 与 Familiar Experts 的视角，避免"千篇一律"；
• 对中文媒体、奖项、政府/协会文件做合规翻译与权威性背书；
• 提前预判可能的 RFE 点（媒体级别、奖项含金量、Future Plans 可执行性），并在初次递交时就把答案写进 Petition。

English: The most common founder-petition flaw is fragmentation. New Weiming Law Group first defined a single identity — a biotech entrepreneur who builds industry influence and converts it into companies and projects — and reorganized every exhibit around that thesis. The petition letter mapped each criterion to evidence, recommendation letters were diversified between independent and familiar experts, Chinese-language materials were properly translated and authenticated, and likely RFE issues were preemptively answered in the initial filing.

Q9. 对生物医药行业同类申请人有什么启示？ | What does this mean for similar biotech applicants?

• 生物医药行业里，很多人的问题不是经历不够，而是没有把经历整理成移民官能迅速理解的职业形象；
• 尤其是做企业、做战略、做项目推进的人，手头其实有大量"证据残件"——投资协议、董事会决议、产品发布、新闻稿、政府备案、合作意向书——只是缺少法律语言把它们串起来；
• 如果你的方向包括 mRNA、ADC、CGT 细胞与基因疗法、AI Drug Discovery、Digital Health、Medical Device、Clinical Research、Biotech VC/PE、Cross-border Licensing 等，EB-1A、NIW 国家利益豁免、O-1、L-1 都值得评估；
• 即便目前持有 H-1B、F-1 OPT/STEM OPT 或 J-1，也可以并行启动 I-140 自我申请，提前锁定优先日（Priority Date），利用 Dual Intent 平稳过渡至 I-485；
• J-1 学者请同步评估 INA §212(e) 与 J-1 豁免路径。

Q10. 想做评估的人应该怎么联系？ | How can prospective applicants get evaluated?

中文：如果您的职业发展长期围绕生物医药、医疗健康、创新项目或企业管理展开，并已在行业中积累了较强的外部认可、公司成果或行业影响力，欢迎联系新未名律所合伙人杨谦律师（qian.yang@nwmlaw.com）做系统评估。在大华府DMV地区，包括马里兰(Maryland)的 Rockville、Bethesda、Gaithersburg 生物医药走廊，以及弗吉尼亚(Virginia)的 Tysons、Reston、Arlington 创新生态，许多客户都是在第一次咨询中才意识到："决定申请质量高低的，不只是做过什么，而是这些经历有没有被准确地讲出来。"

English: If your career has centered on biotech, healthcare, innovation projects, or enterprise leadership, and you have already accumulated external recognition, corporate results, or industry influence, contact partner attorney Qian Yang at New Weiming Law Group (qian.yang@nwmlaw.com) for a systematic evaluation. Across the DMV — from Maryland's I-270 biotech corridor to Virginia's innovation belt — the difference between approval and denial is rarely what you have done, but whether what you have done has been told accurately.

Disclaimer: This case study is provided for general information only and does not constitute legal advice. Outcomes depend on each applicant's specific facts and evidence. Past results do not guarantee future outcomes. Consult a licensed U.S. immigration attorney before acting on any information herein.